Septerna, Inc. (NASDAQ:SEPN) Receives $33.00 Consensus Target Price from Analysts

Septerna, Inc. (NASDAQ:SEPN) has been assigned an average rating of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $33.00.

Several brokerages have weighed in on SEPN. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Wednesday, October 8th. Jones Trading initiated coverage on shares of Septerna in a research report on Tuesday, December 23rd. They set a “buy” rating and a $43.00 target price for the company. Truist Financial initiated coverage on shares of Septerna in a report on Monday, December 15th. They set a “buy” rating and a $34.00 target price for the company. HC Wainwright increased their price target on Septerna from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Finally, Wall Street Zen downgraded Septerna from a “strong-buy” rating to a “buy” rating in a research note on Saturday.

Insiders Place Their Bets

In other Septerna news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $18.06, for a total transaction of $63,228.06. Following the completion of the transaction, the senior vice president directly owned 92,911 shares in the company, valued at approximately $1,677,972.66. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Septerna

A number of institutional investors and hedge funds have recently modified their holdings of SEPN. Russell Investments Group Ltd. acquired a new position in shares of Septerna during the 3rd quarter worth about $36,000. Covestor Ltd raised its holdings in shares of Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after acquiring an additional 1,296 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Septerna by 88.0% in the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock valued at $78,000 after acquiring an additional 1,945 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after acquiring an additional 1,315 shares during the last quarter. Finally, PharVision Advisers LLC acquired a new stake in shares of Septerna in the second quarter worth approximately $107,000.

Septerna Price Performance

SEPN opened at $25.30 on Friday. The firm has a market capitalization of $1.13 billion, a PE ratio of -16.75 and a beta of 3.85. The business’s 50-day moving average is $25.39 and its two-hundred day moving average is $18.79. Septerna has a 1 year low of $4.17 and a 1 year high of $30.50.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The firm had revenue of $21.50 million during the quarter, compared to the consensus estimate of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. As a group, sell-side analysts expect that Septerna will post -7.11 EPS for the current year.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.